Influx Healthtech Ltd

Influx Healthtech Limited was originally incorporated on September 28, 2020 as a Private Limited Company as 'Influx Healthtech Private Limited' with the Registrar of Companies, Central Registration Centre. Company converted from a Private Limited to Public Limited and the name of Company was changed to Influx Healthtech Limited' and a Fresh Certificate of Incorporation upon the conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. Influx Healthtech Limited is a a Mumbai-based healthcare product-focused company that has carved a niche in manufacturing Soft Gelatin, Tablets, Capsules, Liquid Orals, Oral Powders, Liquid fill capsules, Effervescent tablets, Nutra Pallets, Protein Bars, Cookies, Jellies/ Gummies, External preparations like Creams, Gels, Ointments, External Oils, Soaps, etc. for the Nutraceuticals, Cosmetics, Ayurvedic / Herbal, Veterinary Feed Supplements and Homecare segment. The Company is majorly involved in the manufacturing of Dietary/Nutritional Supplements, Gym/Sports Supplements, Veterinary Feeds, Liquid fill capsules, Ayurvedic products and homecare products for small and medium marketing and distribution brands. It specialized in manufacturing of dietary and nutritional supplements and which supports their clients during the product development phase and manufacturing of products which can further be processed into distribution and marketing by different brands. The Company operates three manufacturing plants located in Thane, Maharashtra, which are certified with GMP, HACCP, ISO 22000, and Halal, and are equipped with advanced machinery, a quality control department, and a skilled workforce. It works as a Contract Development and Manufacturing Organization (CDMO), which is a third-party manufacturer. It specialize in a diverse products across several segments, including Dietary/Nutritional Supplements, Cosmetics, Ayurvedic / Herbal, Veterinary Feed Supplements, and Homecare segment. This includes the production of Active Pharmaceutical Ingredients (APIs) and the manufacturing of finished dosage forms such as tablets, capsules, and injectables. The Company came up with a public issue of 61,00,800 equity shares of face value of Rs 10 each by raising funds aggregating to Rs 58.56 crore comprising a fresh issue of 50,00,400 equity shares aggregating to Rs 48 Crore and 11,00,400 equity shares aggregating to Rs 10.56 Crore via offer for sale in June, 2025.